Scholarlink

Purpose of review <p>Glucagon-like peptide-1(GLP-1) analogues have emerged as vital therapies in Managing type 2 diabetes mellitus and obesity, with cardiovascular benefits. With the increased cardiovascular risk associated with rheumatic diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc), GLP-1 analogues, which have proven anti-inflammatory properties in addition to glucose-lowering and weight reduction, may play a potential role in this population group.</p> Recent findings <p>GLP-1 analogues have shown significant potential in improving cardiovascular outcomes, yet their safety and efficacy in rheumatic diseases are yet to be established. Given its known anti-inflammatory properties demonstrated in atherosclerosis prevention, GLP-1 analogues appear to be reasonable additional therapeutic options for rheumatic diseases, especially in high CVD risk population.</p> Summary <p>This review discusses the current evidence on the impact of GLP- 1 analogues on cardiovascular outcomes in patients with rheumatic diseases, evidence gaps, and future research directions. Further investigations emphasizing GLP-1RAs' effect on cardiovascular outcomes of each specific rheumatic disease population are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Role of GLP-1 Receptor Agonists in Rheumatic Diseases: Cardioprotective Potentials, Anti-Inflammatory Effects, and Future Emerging Therapeutic Applications

  • 期刊论文

  • 发表日期：

    2025年9月20日

查看全文
  • Mahmoud Abdelnabi,
  • Nattanicha Chaisrimaneepan,
  • Cristian Castillo-Rodriguez,
  • Nouran Eshak,
  • Megan Sullivan,
  • Ramzi Ibrahim,
  • Hoang Nhat Pham,
  • Juan Farina,
  • Chadi Ayoub,
  • Vivek Nagaraja,
  • Reza Arsanjani

摘要

Purpose of review

Glucagon-like peptide-1(GLP-1) analogues have emerged as vital therapies in Managing type 2 diabetes mellitus and obesity, with cardiovascular benefits. With the increased cardiovascular risk associated with rheumatic diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc), GLP-1 analogues, which have proven anti-inflammatory properties in addition to glucose-lowering and weight reduction, may play a potential role in this population group.

Recent findings

GLP-1 analogues have shown significant potential in improving cardiovascular outcomes, yet their safety and efficacy in rheumatic diseases are yet to be established. Given its known anti-inflammatory properties demonstrated in atherosclerosis prevention, GLP-1 analogues appear to be reasonable additional therapeutic options for rheumatic diseases, especially in high CVD risk population.

Summary

This review discusses the current evidence on the impact of GLP- 1 analogues on cardiovascular outcomes in patients with rheumatic diseases, evidence gaps, and future research directions. Further investigations emphasizing GLP-1RAs' effect on cardiovascular outcomes of each specific rheumatic disease population are warranted.